Perceptive Advisors’s Champions Oncology CSBR Stock Holding History

Perceptive Advisors’s Portfolio CSBR Stock Details CSBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-366,973	Closed	-$1.33M	–	134
2018 Q1	$1.33M	Sell	366,973 -19,567	-5%	-$73K	0.04%	101
2017 Q4	$1.5M	Hold	386,540	–	–	0.05%	94
2017 Q3	$1.42M	Buy	386,540 +19,567	+5%	+$59.9K	0.05%	99
2017 Q2	$943K	Buy	366,973 +1	+0%	+$3	0.05%	95
2017 Q1	$1.16M	Sell	366,972 -5,625	-2%	-$19.7K	0.07%	93
2016 Q4	$942K	Hold	372,597	–	–	0.07%	96
2016 Q3	$625K	Hold	372,597	–	–	0.04%	107
2016 Q2	$801K	Hold	372,597	–	–	0.06%	102
2016 Q1	$1.36M	Hold	372,597	–	–	0.12%	95
2015 Q4	$1.33M	Hold	372,597	–	–	0.1%	81
2015 Q3	$1.99M	Buy	+372,597	New	+$2.43M	0.16%	79

Other funds holding CSBR

BPI

Battery Partners IX Boston, Massachusetts $22.4M AUM 27.71% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors's CSBR Position: Q2 2018 in Review

Perceptive Advisors sold out of Champions Oncology (CSBR) in Q2 2018, closing a stake of 366,973 shares — an estimated $1.33M sold.

Perceptive Advisors first reported a position in CSBR in Q3 2015 and held it in 11 quarters. The position peaked at $1.99M in Q3 2015. 18 funds tracked by Wall St. Rank hold CSBR as of Q2 2018.

Perceptive Advisors reported no remaining Champions Oncology position as of Q2 2018 after selling out during the quarter.
Perceptive Advisors sold 366,973 Champions Oncology shares in Q2 2018, an estimated $1.33M.
Perceptive Advisors first reported a position in Champions Oncology in Q3 2015 and held it in 11 quarters.
Perceptive Advisors's Champions Oncology position peaked at $1.99M in Q3 2015.
18 funds tracked by Wall St. Rank held Champions Oncology as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.